China approves CARsgen Therapeutics satricabtagene autoleucel 'satri-cel' injection
22/06/2026 08:33
China approves CARsgen Therapeutics satricabtagene autoleucel 'satri-cel' injection SHANGHAI, June 22 (Reuters) - China's National Medical Products Administration on Monday said it has approved CARsgen Therapeutics 2171.HK satricabtagene autoleucel “satri-cel” injection.
(Reporting by Andrew Silver in Shanghai; Editing by Christopher Cushing)
Recent news on CARsgen Therapeutics Holdings
See all newsBrief: Carsgen Therapeutics Says CT1190B Receives IND Clearance From NMPA For Relapsed/Refractory Large B-Cell Lymphoma
Brief: Carsgen Therapeutics Says CT0596 Receives IND Clearance From NMPA
Brief: Carsgen Therapeutics Approves Share Repurchase Plan For Up To 30.12 Million Shares
CARsgen Therapeutics climbs on board nod for share buyback
Brief: Carsgen Therapeutics Says NMPA Approves Satricabtagene Autoleucel For Advanced Gastric Cancer